Our findings in individuals recently diagnosed with diabetes provide new evidence associating higher serum NFL levels with DSPN and peripheral nerve dysfunction. The present study advocates NFL as a potential biomarker for DSPN (Diabetologia)
Diabetes News
Category: Screening
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA, and CARMELINA: assessment of a novel staging system for type 2 diabetes
Applying the DSS across T2D clinical trial populations with different CV risk revealed significantly increased risk for ACM and CV death with higher DSS stage. The DSS may benefit from assessment in other T2D populations and with evaluation of the impact of additional outcomes, such as heart failure (Diabetes, Obesity and Metabolism)
The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes
The inclusion of non-autoimmune diabetes is the most likely explanation for the observed lower rate of autoantibody positivity in clinician-diagnosed adult-onset type 1 diabetes. Our data support the utility of islet autoantibody measurement in clinician-suspected adult-onset type 1 diabetes in routine clinical practice (Diabetologia)
The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis
Our population-based study shows that HbA1c screening in adults aged 40–70 years can reduce the time to diabetes diagnosis by a median of 2.2 years compared with routine clinical care (Diabetologia)
The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis
Our population-based study shows that HbA1c screening in adults aged 40–70 years can reduce the time to diabetes diagnosis by a median of 2.2 years compared with routine clinical care (Diabetologia)
Validation of a Risk Prediction Model for Early Chronic Kidney Disease in Patients with Type 2 Diabetes: Data from the German/Austrian DPV Registry
The predictive model achieved moderate discrimination but good calibration in a German/Austrian T2D population suggesting that the model may be relevant for determining CKD risk (Diabetes, Obesity and Metabolism)
Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)
Overall, patients with diabetes should be carefully examined in terms of CV risk stratification (e.g., taking into consideration TOD, renal function, subclinical atherosclerosis, etc.), to define their lipid goals. We strongly suggest that, for such high-risk patients, LDL-C target should be achieved as early as possible to maximize CVD prevention (Cardiovascular Diabetology)
Care processes in people in remission from type 2 diabetes: A cohort study using the National Diabetes Audit
People coded with remission of type 2 diabetes were less likely to receive diabetes care processes than those without such coding (Diabetic Medicine)
Screening all older adults aged 40-70 years would find undiagnosed type 2 diabetes cases at least two years earlier
Our study provides the first population-based estimate of the impact of HbA1c-based screening on reducing the time to diabetes diagnosis. In UK Biobank (Diabetologia )
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes
A personalized alternative to annual screening in type 1 diabetes can substantially reduce both the time with undetected kidney disease and the frequency of urine testing (Diabetes Care)
Long-term Outcomes Among Young Adults With Type 2 Diabetes Based on Durability of Glycemic Control: Results From the TODAY Cohort Study
Higher baseline HbA1c concentration and FG variability during year 1 accurately predicted youth with T2D who will experience metabolic decompensation and comorbidities. These values may be useful tools for clinicians when considering early intensification of therapy (Diabetes Care)
MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modelling
Sixteen microRNAs met the criteria for biomarker selection (Diabetologia)
The measurement of autoantibodies to insulin informs diagnosis of diabetes in a childhood population negative for other autoantibodies
Using highly-sensitive assays, testing for three autoantibodies fails to detect islet autoimmunity in approximately 1/20 children diagnosed with type 1 diabetes. Testing for IAA in children <5 years and GADA in those >10 years was the most effective strategy for detecting islet autoimmunity. The ability to test for all islet autoantibodies should inform clinical decisions and make screening for monogenic diabetes more cost-effective (Diabetic Medicine)
Metabolic signatures of β-cell destruction in type 1 diabetes
In the present study, metabolic signatures were shown to be useful in identifying type 1 diabetes at different clinical stages, and 3-phenylpropionic acid and hypotaurine are novel biomarkers for identifying new-onset type 1 diabetes, suggesting the involvement of the gut bacterial environment, anti-oxidant mechanisms through the hypotaurine-taurine pathway and methylated deoxyribonucleic acid fragmentation in the process of β-cell destruction (Journal of Diabetes Investigation)
Recommendations for Screening Children and Adolescents for Prediabetes and Type 2 Diabetes
In this issue of JAMA, the US Preventive Services Task Force (USPSTF) addresses this important issue with a new Recommendation Statement on screening for prediabetes and type 2 diabetes in children and adolescents based on an Evidence Report and Systematic Review of the evidence on screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant persons younger than 18 year (JAMA)
A Longitudinal Assessment of Diabetes Autoantibodies in the SEARCH for Diabetes in Youth study
DA status likely remains stable in the first 7 years after diabetes diagnosis. Younger age at diabetes diagnosis and longer duration were associated with less persistence of DAs. Measuring DAs after initial presentation may aid in diabetes classification but not likely in predicting the clinical course (Pediatric Diabetes)
Attendance in a national screening program for diabetic retinopathy: a population-based study of 205,970 patients
In a national cohort of 205,970 patients, almost half of the patients attended DR screening later than scheduled or dropped out after first screening episode. This was, in particular, true for patients with any levels of DR at baseline. DR progression in patients with delayed attendance, increased with the number of missed appointments (Acta Diabetologica)
Digital innovations for retinal care in diabetic retinopathy
Advances in digital health have created an ecosystem ripe for telemedicine in the field of DR to thrive. Stakeholders and policymakers should adopt a participatory approach to ensure sustained implementation of these technologies after the COVID-19 pandemic (Acta Diabetologica)
Diabetic retinopathy screening in the emerging era of artificial intelligence
Although clinically implemented AI-based diabetic retinopathy screening, integration of mobile devices and ocular telemedicine are still in their infancy, the technology is evolving rapidly and there is little doubt that these concepts will be able to optimise diabetic retinopathy screening within a few years (Diabetologia)
Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study
Our results show that initial screening for islet autoantibodies at two ages (2 years and 6 years) is sensitive and efficient for public health translation but might require adjustment by country on the basis of population-specific disease characteristics (The Lancet Diabetes & Endocrinology)
- 1
- 2
- 3
- …
- 11
- Next Page »
Glycosmedia is also available as an App: